Press Release
<< Back
Verastem Announces Presentations at the 2013 AACR-NCI-EORTC International Conference
Title: Phase 1/1b Study of the FAK Inhibitor Defactinib
(VS-6063) in Combination with Weekly Paclitaxel for Advanced Ovarian
Cancer
Abstract #: 937
Date and Time:
Session: Poster Session A;
Clinical Trials 1
Location: Exhibit Hall C-D
Title: Defactinib (VS-6063) Targets Cancer Stem Cells Directly
and Through Inhibition of Tumor-Associated Macrophages and Cytokine
Production
Abstract #: 863
Date and Time:
Session: Poster
Session B; Therapeutic Agents: Small Molecule Kinase Inhibitors 2
Location:
Exhibit Hall C-D
Title: Malignant Mesothelioma Lacking Merlin Shows Enhances
Sensitivity to the FAK Inhibitor Defactinib (VS-6063): Elucidation of
the Merlin-FAK Relationship
Abstract #: 765
Date and
Time:
Session ID:
Poster Session C; Therapeutic Agents: Small Molecule Kinase Inhibitors 3
Location:
Exhibit Hall C-D
Title:
Abstract
#: 848
Date and Time:
Session ID: Poster Session A; Biomarkers
Location:
Exhibit Hall C-D
Title: FAK Inhibitor Defactinib (VS-6063) Enhances the Efficacy
of Paclitaxel and Preferentially Targets Ovarian Cancer Stem Cells
Abstract
#: 899
Date and Time:
Session ID: Poster Session C; Therapeutic Agents:
Small Molecule Kinase Inhibitors 3
Location: Exhibit Hall C-D
Title: Dual mTORC1/2 and PI3K Inhibitor VS-5584 Preferentially
Targets Cancer Stem Cells
Abstract #: 889
Date and
Time:
Session ID:
Poster Session B; Cancer Stem Cells 2
Location: Exhibit Hall
C-D
About Defactinib
Defactinib (VS-6063) is an oral compound designed to target cancer stem
cells through the potent inhibition of focal adhesion kinase (FAK).
Cancer stem cells are an underlying cause of tumor resistance to
chemotherapy, recurrence and ultimate disease progression. Research by
About VS-5584
VS-5584 is an orally available compound that has demonstrated potent and
highly selective in vitro inhibitory activity against mTORC1, mTORC2 and
the class 1 PI3K isoforms. In preclinical studies, VS-5584 has been
shown to reduce the percentage of cancer stem cells and induce tumor
regression in taxane-resistant models.
About
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development of the Company’s compounds, including
defactinib, VS-4718 and VS-5584 and the Company’s FAK and diagnostic
programs generally, the timeline for clinical development and regulatory
approval of the Company’s compounds, the expected timing for the
reporting of data from ongoing studies, the structure of the Company’s
planned clinical trials and the Company’s ability to fund operations.
The words “anticipate,” “appear,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,”
“will,” “would,” “could,” “should,” “continue,” and similar expressions
are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement. Applicable risks and uncertainties include
the risks that the preclinical testing of the Company’s compounds and
preliminary data from clinical trials may not be predictive of the
results or success of later clinical trials, that data may not be
available when we expect it to be, that the Company will be unable to
successfully complete the clinical development of its compounds,
including defactinib, VS-4718 and VS-5584, that the development of the
Company’s compounds will take longer or cost more than planned, and that
the Company’s compounds will not receive regulatory approval or become
commercially successful products. Other risks and uncertainties include
those identified under the heading “Risk Factors” in the Company’s
Annual Report on Form 10-K for the year ended
Source:
Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com
